{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:32:16Z","timestamp":1785486736661,"version":"3.56.0"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Cancer patients use cannabis for medicinal purposes; however, few studies have examined hematology patients\u2019 use of cannabis and no research to our knowledge has investigated the use of cannabis amongst hematology patients before and after hematopoietic stem cell transplant (HCT). The purpose of this longitudinal survey study was to assess aspects of cannabis use in patients who underwent HCT. Eligible patients (N = 30) completed two surveys before and 90 days following their HCT. The surveys inquired about several aspects of cannabis (e.g., rate of use, beliefs and attitudes, access to information) and physical and psychological outcomes (e.g., anxiety, comorbidities, graft-versus-host-disease). Rates of cannabis use decreased following HCT (n = 14, 46% to n = 11, 40%). Conversations on cannabis that were initiated by an oncology health care provider increased post-transplant (n = 3, 10% to n = 11, 37%). This coincided with fewer who were smoking cannabis as a primary consumption method (n = 5, 38 to n = 2, 18) and an increase in the use of pharmaceutical cannabinoid products (n = 4, 13% to n = 6, 21%) as well as oils and topicals. Of the total sample, 63% (n = 17) experienced post-treatment complications and 33% (n = 10) developed GVHD, six of whom where recent cannabis users. This study provided insight into cannabis use amongst HCT patients and warrants further research with this population, including more exploration of the relationship between GVHD and cannabis.<\/jats:p>","DOI":"10.3390\/ijerph22070990","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:44:41Z","timestamp":1750761881000},"page":"990","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cannabis in Hematology Survey Study (CHESS): A Longitudinal Investigation on Uses, Attitudes, and Outcomes of Cannabis Among Hematology Patients Undergoing Hematopoietic Stem Cell Transplant"],"prefix":"10.3390","volume":"22","author":[{"given":"Andrew I. G.","family":"McLennan","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Regina, Regina, SK S4S 0A2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reanne","family":"Booker","sequence":"additional","affiliation":[{"name":"Palliative Care, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9678-6703","authenticated-orcid":false,"given":"Cameron","family":"Roessner","sequence":"additional","affiliation":[{"name":"Pharmacy Services, Arthur J.E. Child Comprehensive Cancer Centre, Alberta Health Services, Calgary, AB T2N 4N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Kerba","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Aviram, J., Lewitus, G.M., Vysotski, Y., Abu Amna, M., Ouryvaev, A., Procaccia, S., Cohen, I., Leibovici, A., Akria, L., and Goncharov, D. (2022). The effectiveness and safety of medical cannabis for treating cancer related symptoms in oncology patients. Front. Pain Res., 3.","DOI":"10.3389\/fpain.2022.861037"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3747\/co.25.3983","article-title":"Rates of cannabis use in patients with cancer","volume":"25","author":"Martell","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vinette, B., C\u00f4t\u00e9, J., El-Akhras, A., Mrad, H., Chicoine, G., and Bilodeau, K. (2022). Routes of administration, reasons for use, and approved indications of medical cannabis in oncology: A scoping review. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09378-7"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO Guideline","volume":"42","author":"Braun","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Amin, S., Chae, S.W., Kawamoto Philips, K.T., and Pokhrel, P. (2024). Cannabis use among cancer patients and survivors in the United States: A systematic review. JNCI Cancer Spectr., 8.","DOI":"10.1093\/jncics\/pkae004"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1002\/cncr.30879","article-title":"Cannabis use among patients at a comprehensive cancer center in a state with legalized medicinal and recreational use","volume":"123","author":"Pergam","year":"2017","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1182\/bloodadvances.2023010208","article-title":"Circulating microbial cell\u2013free DNA is increased during neutropenia after hematopoietic stem cell transplantation","volume":"7","author":"Blair","year":"2023","journal-title":"Blood Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bbmt.2017.01.070","article-title":"Clinical outcome of autologous hematopoietic cell transplantation in adult patients with acute myeloid leukemia: Who may benefit from autologous hematopoietic cell transplantation?","volume":"23","author":"Yoon","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jpainsymman.2011.08.011","article-title":"Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation","volume":"44","author":"Cohen","year":"2012","journal-title":"J. Pain Symptom Manag."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gray, T.F., Temel, J.S., and El-Jawahri, A. (2021). Illness and prognostic understanding in patients with hematologic malignancies. Blood Rev., 45.","DOI":"10.1016\/j.blre.2020.100692"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1038\/s41409-022-01764-w","article-title":"Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: A multicenter chart review","volume":"57","author":"Holtan","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/cncr.20613","article-title":"Acute graft-versus-host disease: Pathophysiology, clinical manifestations, and management","volume":"101","author":"Couriel","year":"2004","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Knight, J.M., Moynihan, J.A., Lyness, J.M., Xia, Y., Tu, X., Messing, S., Hunter, B.C., Huang, L.-S., Obi, R.O., and Gaisser, D. (2014). Peri-transplant psychosocial factors and neutrophil recovery following hematopoietic stem cell transplantation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099778"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1124\/jpet.111.182717","article-title":"Targeting cannabinoid receptors as a novel approach in the treatment of graft-versus-host disease: Evidence from an experimental murine model","volume":"338","author":"Pandey","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.bbmt.2015.05.018","article-title":"Cannabidiol for the prevention of graft-versus-host-disease after allogeneic hematopoietic cell transplantation: Results of a phase II study","volume":"21","author":"Yeshurun","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Irrera, N., Bitto, A., Sant\u2019Antonio, E., Lauro, R., Musolino, C., and Allegra, A. (2021). Pros and cons of the cannabinoid system in cancer: Focus on hematological malignancies. Molecules, 26.","DOI":"10.3390\/molecules26133866"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood.2020004871","article-title":"Signaling through the type 2 cannabinoid receptor regulates the severity of acute and chronic graft-versus-host disease","volume":"137","author":"Yuan","year":"2021","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3747\/co.27.5615","article-title":"Health care provider preferences for, and barriers to, cannabis use in cancer care","volume":"27","author":"McLennan","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The Edmonton symptom assessment system 25 years later: Past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J. Pain Symptom Manag."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","article-title":"Validation of the Edmonton symptom assessment scale","volume":"88","author":"Chang","year":"2000","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Noel, C.W., Forner, D., Chepeha, D.B., Baran, E., Chan, K.K., Parmar, A., Husain, Z., Karam, I., Hallet, J., and Coburn, N.G. (2021). The Edmonton symptom assessment system: A narrative review of a standardized symptom assessment tool in head and neck oncology. Oral Oncol., 123.","DOI":"10.1016\/j.oraloncology.2021.105595"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s11469-020-00270-8","article-title":"The fear of COVID 19 scale: Development and initial validation","volume":"20","author":"Ahorsu","year":"2020","journal-title":"Int. J. Ment. Health Addict."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"\u00c7elik, S., G\u00fcven, Z.T., \u0130pekten, F., Keklik, M., \u00dcnal, A., and Kaynar, L. (2022). Evaluation of COVID-19 fear and quality of life in patients with haematopoietic stem cell transplantation during the COVID-19 pandemic. Eur. J. Cancer Care, 31.","DOI":"10.1111\/ecc.13604"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Erdo\u011fan, A.P., Ekinci, F., Acar, \u00d6., and G\u00f6ksel, G. (2022). Level of COVID-19 fear in cancer patients. Middle East Curr. Psychiatry, 29.","DOI":"10.1186\/s43045-022-00181-5"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sigorski, D., Sobczuk, P., Osmola, M., Ku\u0107, K., Walerzak, A., Wilk, M., Ciszewski, T., Kope\u0107, S., Hry\u0144, K., and Rutkowski, P. (2020). Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy. ESMO Open, 5.","DOI":"10.1136\/esmoopen-2020-000970"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Almogi-Hazan, O., Khuja, I., Ritter, S., and Or, R. (2020). The highs and lows of cannabis in cancer treatment and bone marrow transplantation. Rambam Maimonides Med. J., 11.","DOI":"10.5041\/RMMJ.10391"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Seltzer, E.S., Watters, A.K., MacKenzie, D., Granat, L.M., and Zhang, D. (2020). Cannabidiol (CBD) as a promising anti-cancer drug. Cancers, 12.","DOI":"10.3390\/cancers12113203"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Valenti, C., Billi, M., Pancrazi, G.L., Calabria, E., Armogida, N.G., Tortora, G., Pagano, S., Barnaba, P., and Marinucci, L. (2022). Biological effects of cannabidiol on human cancer cells: Systematic review of the literature. Pharmacol Res., 181.","DOI":"10.1016\/j.phrs.2022.106267"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ghimire, S., Weber, D., Mavin, E., Wang, X.N., Dickinson, A.M., and Holler, E. (2017). Pathophysiology of GvHD and other HSCT-related major complications. Front Immunol., 8.","DOI":"10.3389\/fimmu.2017.00079"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Teshima, T., and Hill, R. (2021). The pathophysiology and treatment of graft-versus-host disease: Lessons learnt from animal models. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.715424"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Khuja, I., Yekhtin, Z., Or, R., and Almogi-Hazan, O. (2019). Cannabinoids reduce inflammation but inhibit lymphocyte recovery in murine models of bone marrow transplantation. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030668"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Hawley, P., Gobbo, M., and Afghari, N. (2020). The impact of legalization of access to recreational cannabis on Canadian medical users with cancer. BMC Health Serv. Res., 20.","DOI":"10.1186\/s12913-020-05756-8"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cncr.33906","article-title":"A Coala-T-Cannabis survey study of breast cancer patients\u2019 use of cannabis before, during, and after treatment","volume":"128","author":"Weiss","year":"2022","journal-title":"Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000493567","article-title":"Medical cannabis use by Hodgkin lymphoma patients: Experience of a single center","volume":"140","author":"Sarid","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Baral, A., Diggs, B.A., El Fellah, R.M., McCarley, C., Penedo, F., Martinez, C., and Vidot, D.C. (2024). Cannabis use among cancer patients during active treatment: Findings from a study at an NCI-designated cancer center. Cancer Med., 13.","DOI":"10.1002\/cam4.70384"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Ferreyro, B.L., Munshi, L., Saskin, R., Cheung, M.C., Gupta, V., Thyagu, S., Wunsch, H., and Scales, D.C. (2023). Symptom trajectory in hematopoietic stem cell transplantation recipients who survive critical illness. CHEST Crit. Care, 1.","DOI":"10.1016\/j.chstcc.2023.100004"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.2017.76.1221","article-title":"Medical oncologists\u2019 beliefs, practices, and knowledge regarding marijuana used therapeutically: A nationally representative survey study","volume":"36","author":"Braun","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/jncimonographs\/lgab012","article-title":"Cannabis and the cancer patient","volume":"58","author":"Braun","year":"2021","journal-title":"JNCI Monogr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1200\/OP.21.00714","article-title":"Oncology fellows\u2019 clinical discussions, perceived knowledge, and formal training regarding medical cannabis use: A national survey study","volume":"18","author":"Patell","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hachem, Y., Abdallah, S.J., Rueda, S., Wiese, J.L., Mehra, K., Rup, J., Cowan, J., Vigano, A., and Costiniuk, C.T. (2022). Healthcare practitioner perceptions on barriers impacting cannabis prescribing practices. BMC Complement. Med. Ther., 22.","DOI":"10.1186\/s12906-022-03716-9"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Hadid, T., Biedny, A., Mamdani, H., Azmi, A., Kim, S., Jang, H., Uprety, D., Al Hallak, M.N., and Sukari, A. (2024). Association between cannabis use and clinical outcomes in patients with solid malignancies receiving immune checkpoint inhibitors. Ther. Adv. Vaccines Immunother., 12.","DOI":"10.1177\/25151355241309095"}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/22\/7\/990\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:57:19Z","timestamp":1760032639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/22\/7\/990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ijerph22070990"],"URL":"https:\/\/doi.org\/10.3390\/ijerph22070990","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}